Molecular docking studies of some novel 2 & 3-(4-aminobenzamido) benzoic acid derivatives as DHFR inhibitors for treatment of tuberculosis

Prashik B. Dudhe¹,²* Hardik G. Bhatt²

¹Sinhgad College of Pharmacy, Department of Pharmaceutical Chemistry, Vadgaon(Bk), Pune 410041, India.
²Institute of Pharmacy, Nirma University. G. Highway, Ahmedabad-382481, India.

Abstract : A Novel series 2 & 3-(4-aminobenzamido) benzoic acid derivatives were designed virtually considering the basic pharmacophore N-(3,5-bis (trifluoromethyl) phenyl)-5-chloro-2-hydroxybenzamide. The energy minimized conformers of each molecule were generated and docked with M. tuberculosis DHFR enzyme with PDB id: 1DF7 using Autodock 4.2.5.1. Most of the molecules have shown significant binding interaction with the receptor. Among the test compounds, DX-35, DY-24, DX-18, DX-31 & DY-23 have shown highest free energy of binding -9.51 to -8.92 kcal/mol and also the very good estimated inhibitory constant in a range of 0.11 to 0.29 Ki μM, which is comparable to that of the reference standard methotrexate and the standard Anti-Tb drug Ciprofloxacin.

Keywords : Docking, Methotrexate, Ciprofloxacin, Autodock, Benzamide & Benzoic acid.

Introduction

In current years as per WHO TB is the tenth primary cause of death worldwide and the leading cause from a single infectious agent, ranking above HIV/AIDS. In 2017, there were an estimated 1.3 million TB (Tuberculosis) deaths among HIV-negative people and an additional 300 000 deaths among HIV-positive people. An estimated 10 million people fell ill with TB in 2017. Around 558 000 new cases of resistance was found in 2017.¹

Dihydrofolate reductase (DHFR) is an important enzyme in the folate metabolic pathway which is necessary for the biosynthesis of essential amino acids required for DNA, RNA, and protein synthesis in eukaryotic and prokaryotic cells. Inhibition of the enzyme leads to the arrest of DNA synthesis causing cell death. Dihydrofolate reductase is one of the well-established targets, where around 100 or more 3D-structures

Prashik B. Dudhe et al / International Journal of PharmTech Research, 2020,13(3): 261-271.
DOI= http://dx.doi.org/10.20902/IJPTR.2019.130317
submitted to Protein Data bank. DHFR is the sole source of tetrahydrofolate Thus, the enzyme has already attracted a lot of researcher for the anticancer (methotrexate)\(^2\)\(^-\)\(^3\), antibacterial (trimethoprim)\(^4\), antimalarial (pyrimethamine)\(^5\) drugs and anticoxiela burnetti\(^6\). Moreover, specific inhibitors of *Mycobacterium tuberculosis* DHFR (*mtDHFR*) which are active against live *M. tuberculosis* cells have been developed, suggesting that such inhibitors may be useful for treating tuberculosis\(^7\)\(^-\)\(^15\).

In the Protein (PDB: 1DF7) a sequence alignment comparison between human and *M. tuberculosis* DHFRs indicates only 26 % sequence identity and, hence, key differences in the active sites leading to quite specific suggestions for design of new selective inhibitors of *M. tuberculosis* DHFR.

In recent years amino benzamide derivative have gain lot of importance for their potential as highly effective in combating *Mycobacterium tuberculosis* Infection\(^16\)\(^-\)\(^17\) we also found N-(3,5-bis (trifluoromethyl) phenyl)-5-chloro-2-hydroxybenzamide (IMD-0354) as a lead compound. IMD-0354 is a potent inhibitor of 1ƙB kinase β, and was reached till Phase I/II clinical trials for both atopic dermatitis and chronic obstructive pulmonary disease\(^18\).

By considering the above facts and also that this compounds are already in human trials, we wish to report the docking studies of some novel 35 newly designed (Table No.1) 2 & 3-(4-aminobenzamido) benzoic acid derivatives with *mtDHFR*.

![Fig 1. Drugs under clinical trials](image1)

\[ N-(3,5\text{-bis(trifluoromethyl)phenyl})-5\text{-chloro-2-hydroxybenzamide} \]

![Fig 2. The structure of *mtDHFR* (1DF7).](image2)
Experimental

Materials and Methods

All computational studies were carried out using Autodock 4.2.5.1 (version: 1.5.6) installed in a single machine running on a 2.10 GHz Intel core2 duo processor with 2GB RAM and 500 GB hard disk with windows 7 ultimate as an operating system.

In the present study, the X-ray crystal structure of the antimicrobial agent methotrexate bound to mtDHFR was obtained from the Protein Data Bank (http://www.rscb.org/pdb/) (Fig. 2). (PDB ID: 1DF7). The protein consists of 159 amino acid and resolution of 1.7 to 2.0 Å was processed by removing water and methotrexate and energy minimization of this clean protein was carried out in the software Tripos’s Sybyl-X 2.0 using the Tripod force field force field and combination of 10,000 steepest descent and conjugate gradient steps with 0.02 Å step size. 2D and 3D structures of 2 & 3-(4-aminobenzamido) benzoic acid derivatives were drawn and Geometry optimization was also performed using Sybyl-X 2.0. The energy minimized protein and geometry optimized structures of compounds were processed in MGLtools1.5.4. Docking simulation was carried out in Autodock 4.2.19-20

Autodock 4.2.5.1 was used to explore the binding conformation of methotrexate and active test molecules. The Autodock Tools package version 1.5.4 was employed to generate the docking input files and to analyze the docking results. Nonpolar hydrogens present in the protein were merged along with removal of water molecules. For the docking, a grid spacing of 0.375 Å and 60 x 60 x 60 number of points was used. The grid was centered on the ligand coordinates i.e. methotrexate. Autodock generated 25 possible binding conformations, i.e. 25 runs for each docking by using Genetic Algorithm (GA-LS) searches. A default protocol was applied, with an initial population of 150 randomly placed individuals, a maximum number of 2.5 x 105 energy evaluations, and a maximum number of 2.7 x 104 generations. A mutation rate of 0.02 and a crossover rate of 0.8 were used.

The analysis of binding free energy and interactions of ligands with residues at active site was carried out by using Pymol, Openbabel and Discovery studio 3.5. To validate the use of the Autodock program, redocking was performed on the reference compound methotrexate. Autodock successfully reproduced the experimental binding conformations of the reference drug methotrexate with acceptable root-mean-square deviation (RMSD) of 0.69 Å.

Table No.1: Novel 35 newly designed 2 & 3-(4-aminobenzamido) benzoic acid derivatives

![General structure of 2 & 3-(4-aminobenzamido) benzoic acid derivatives](image_url)
| Sr. No. | Comp. Code | R  | R’ | R’1          | R’2 | R’3 |
|-------|------------|----|----|--------------|-----|-----|
| 1.    | D-5        | H  | H  | -COOC₂H₅     | H   | H   |
| 2.    | D-6        | H  | H  | -COOC₆H₇     | H   | H   |
| 3.    | D-9        | H  | H  | -COOC₈H₁₀    | H   | H   |
| 4.    | D-8        | H  | H  | -N=O-N=CH₃   | H   | H   |
| 5.    | D-10       | H  | H  | H            | C=N-N=CH₃ | H   |
| 6.    | D-16       | H  | H  | H            | Cl  | F   |
| 7.    | D-22       | H  | H  | O=N          | H   | H   |
| 8.    | D-23       | H  | H  | O=N-C₆H₄     | H   | H   |
| 9.    | DX-1       | H  | H  | H            | H   | H   |
| 10.   | DX-3       | H  | H  | O=N          | H   | H   |
| 11.   | DX-5       | H  | H  | O=N          | H   | H   |
| 12.   | DX-7       | H  | H  | O=N          | H   | H   |
| 13.   | DX-9       | H  | H  | O=N          | H   | H   |
| 14.   | DX-12      | H  | H  | O=N          | H   | H   |
| 15.   | DX-14      | H  | H  | O=N          | H   | H   |
| 16.   | DX-18      | H  | H  | O=N          | H   | H   |
| 17.   | DX-20      | H  | H  | O=N          | H   | H   |
| 18.   | DX-26      | H  | H  | O=N          | H   | H   |
| 19.   | DX-27      | H  | H  | O=N          | H   | H   |
| 20.   | DX-28      | H  | H  | O=N          | H   | H   |
| 21.   | DX-29      | H  | H  | O=N          | H   | H   |
|   | Code | R1  | R2  | R3  | R4  |
|---|------|-----|-----|-----|-----|
| 22 | DX-30 | H   | H   | H   | H   |
| 23 | DX-31 | H   | H   | H   | H   |
| 24 | DX-33 | H   | H   | H   | H   |
| 25 | DX-34 | H   | H   | H   | H   |
| 26 | DX-35 | H   | H   | H   | H   |
| 27 | DY-2  | H   | H   | H   | H   |
| 28 | DY-6  | H   | H   | H   | H   |
| 29 | DY-9  | H   | H   | H   | H   |
| 30 | DY-11 | H   | H   | H   | H   |
| 31 | DY-12 | H   | H   | H   | H   |
| 32 | DY-18 | H   | H   | H   | H   |
| 33 | DY-15 | H   | H   | H   | H   |
| 34 | DY-23 | H   | H   | H   | H   |
| 35 | DY-24 | H   | H   | H   | H   |
Results and Discussion

Molecular Docking and Binding Mode Analysis

An in-silico method has been used to generate the candidate model of mtDHFR derivatives using AUTODOCK-4 software. The 3D & 2D structures of the ligand molecule were built considering the pharmacophoric feature of the compound methotrexate. The ADT package was employed here to generate the docking input files of the ligand.

The highest ranking model was used further for ligand docking studies. Docking study also shows that model can be used for virtual screening of Anti-TB activity. The docking studies were carried out by using above mentioned validated docking protocol. The free energy of binding reflects the interaction energy between the ligand-protein complex and which has the lowest energy showed more stable interactions. Docking simulation results can be seen in Table 2.

Table 2 Results of docking studies

| Sr. No. | Comp. Code | Free energy of binding (kcal/mole) | Estimated inhibitory constant, Ki (μM) | Receptor-Ligand Interactions |
|---------|------------|-----------------------------------|--------------------------------------|-----------------------------|
| 1.      | DX-35      | -9.51                             | 0.11                                 | ALA7, THR46                |
| 2.      | DY-24      | -9.13                             | 0.20                                 | ALA7, THR46, TYR100, TRP6, GLY96 |
| 3.      | DX-18      | -8.99                             | 0.26                                 | ALA7, TRP22                |
| 4.      | DX-31      | -8.96                             | 0.27                                 | ALA7, THR46                |
| 5.      | DY-23      | -8.92                             | 0.29                                 | ALA7, TYR100, ILE94, ILE20 |
| 6.      | DY-9       | -8.82                             | 0.34                                 | ALA7, ILE94, ARG32         |
| 7.      | DY-2       | -8.7                              | 0.42                                 | ALA7, THR46, SER49, ASP19, GLY18, GLY96 |
| 8.      | DX-1       | -8.66                             | 0.45                                 | ILE94, ARG32, ARG60, GLN28 |
| 9.      | DX-14      | -8.64                             | 0.46                                 | ALA7, LEU24                |
| 10.     | DY-12      | -8.63                             | 0.47                                 | ALA7, TRP6, ILE5, TRP22   |
| 11.     | DX-27      | -8.59                             | 0.50                                 | TYR100, TRP22, ILE94, ASP27 |
| 12.     | D-10       | -8.57                             | 0.52                                 | ALA7, TRP22                |
| 13.     | DX-28      | -8.57                             | 0.52                                 | ALA7, ASP27, TRP22, ILE94 |
| 14.     | DX-33      | -8.5                              | 0.58                                 | ALA7                      |
| 15.     | DX-9       | -8.42                             | 0.68                                 | ALA7, TRP22, SER49         |
| 16.     | DX-12      | -8.4                              | 0.70                                 | ALA7, TRP22, ILE14        |
| 17.     | DX-20      | -8.12                             | 1.12                                 | ALA7, TRP22                |
| 18.     | DY-11      | -8.1                              | 1.15                                 | ALA7, TYR100, ASP27, ASP19, SER49 |
| 19.     | D-23       | -8.07                             | 1.21                                 | TRP22                     |
| 20.     | DX-29      | -8.05                             | 1.25                                 | ALA7, TYR100, ASP27        |
| 21.     | DY-18      | -8.05                             | 1.26                                 | ALA7, ILE5, TRP22          |
| 22.     | DX-30      | -8.04                             | 1.27                                 | ALA7, ILE20, ASP27, THR113 |
|   | Compound | ΔG (kcal/mol) | Inhibitory Constant (Ki μM) | Important Residues |
|---|-----------|---------------|-----------------------------|-------------------|
| 23. | DY-6     | -8.04         | 1.28                        | ALA7, ASP27, ILE94, SER49, GLY96 |
| 24. | DX-7     | -8.01         | 1.35                        | TYR100, ASP27, SER49 |
| 25. | DX-3     | -7.93         | 1.55                        | TYR100, ASP27, ILE20 |
| 26. | DX-34    | -7.78         | 1.97                        | ALA7, TYR100, ASP19, SER49 |
| 27. | DY-15    | -7.75         | 2.07                        | ALA7, ILE94, ARG32 |
| 28. | DX-5     | -7.72         | 2.18                        | TYR100, ASP27 |
| 29. | D-8      | -7.64         | 2.52                        | ALA7, TRP22 |
| 30. | DX-26    | -7.54         | 2.96                        | ALA7, ILE94, ASP27, SER49 |
| 31. | D-22     | -7.33         | 4.21                        | TRP22, ASP27 |
| 32. | D-9      | -7.17         | 5.58                        | ALA7, ILE94 |
| 33. | D-6      | -7.12         | 6.08                        | TRP6, GLN28 |
| 34. | D-16     | -6.83         | 9.78                        | TYR100, ASP27 |
| 35. | D-5      | -6.77         | 10.85                       | ILE94, ASP27 |

Ciprofloxacin: ΔG = -7.58 kcal/mol, Inhibitory Constant = 2.79 Ki μM

**Methotrexate (Reference standard)**: ΔG = -10.21 kcal/mol, Inhibitory Constant = 32.59 Ki μM

It was found that compound DX-35, DY-24, DX-18, DX-31 & DY-23 have a significant favorable free energy of binding in a range of -9.51 to -8.92 kcal/mol and also the very good estimated inhibitory constant in a range of 0.11 to 0.29 Ki μM which seems to be much close to that of the reference standard methotrexate for the energy minimized mtDHFR protein.

The docking studies were also compared with the standard Anti Tb drug Ciprofloxacin. The residues ALA7, TYR100, ASP27 & ILE94 are important in making important hydrogen interactions. The best conformer generated in docking showed same interactions as shown in Figure 3. The 2D diagram of important interactions between active site residues and all the compounds is shown in figure 4& 5.

**Figure 3:**
(A) Docked conformer of Methotrexate (docked conformer shown in yellow and original pose of Methotrexate shown in green fluorescent color)  
(B) 2D Docking Interactions of Methotrexate in with mtDHFR
Figure 4: 2D Interaction diagram for 2 & 3-(4-aminobenzamido) benzoic acid derivatives
Figure 5: 2D Interaction diagram for 2 & 3-(4-aminobenzamido) benzoic acid derivatives
Conclusion

The molecular docking studies illustrate that the active analogs DX-35, DY-24, DX-18, DX-31 & DY-23 adopt an acceptable conformation within the active site of mtDHFR protein. Along with the significant binding interactions have well been pointed out from the above figures. The estimated inhibitory constant of all compounds are in a good range. On the basis of the above findings, these compounds can be further subjected to the QSAR Prediction model and help in rational design of novel and potent mtDHFR inhibitors for the treatment of Tuberculosis.

Acknowledgement

The authors gratefully acknowledge the contributions of Professor M.N. Navale, President and Dr. (Mrs.) S.M. Navale, Secretary, Sinhgad Technical Education Society, Pune, for constant motivation and encouragement and also thankful to Nirma University, Ahmedabad, India for providing necessary facilities.

References:

1. World Health Organization, Tuberculosis (TB), 2018.
2. Rajagopalan PR, Zhang Z, McCourt L, Dwyer M, Benkovic SJ, Hammers GG. Interaction of dihydrofolate reductase with methotrexate: ensemble and single-molecule kinetics. Proceedings of the National Academy of Sciences. 2002 Oct 15;99(21):13481-6.
3. Antosiewicz A, Jarmuła A, Przybylska D, Mosieniak G, Szczepanowska J, Kowalkowska A, Rode W, Cieśla J. Human dihydrofolate reductase and thymidylate synthase form a complex in vitro and co-localize in normal and cancer cells. Journal of Biomolecular Structure and Dynamics. 2017 May 19;35(7):1474-90.
4. Matthews DA, Bolin JT, Burridge JM, Filman DJ, Volz KW, Kaufman BT, Beddell CR, Champness JN, Stammers DK, Kraut J. Refined crystal structures of Escherichia coli and chicken liver dihydrofolate reductase containing bound trimethoprim. Journal of Biological Chemistry. 1985 Jan 10;260(1):381-91.
5. Anderson AC. Targeting DHFR in parasitic protozoa. Drug discovery today. 2005 Jan 15;10(2):121-8.
6. de Souza FR, Guimarães AP, Cuya T, de Freitas MP, Goncalves AD, Forgione P, Costa França TC. Analysis of Coxiella burnetti dihydrofolate reductase via in silico docking with inhibitors and molecular dynamics simulation. Journal of Biomolecular Structure and Dynamics. 2017 Oct 3;35(13):2975-86.
7. Arunkumar S, Ilango K, Manikandand KS, Sudha M, Ramalakshmi N. Synthesis, Characterisation and Biological Evaluation of some novel 2, 5-Disubstituted-1, 3, 4-oxadiazole derivatives of Gallic acid. International Journal of Chem Tech. 2009;1:1094-9.
8. Dewangan D, Pandey A, Sivakumar T, Rajavel R, Dubey RD. Synthesis of some novel 2, 5-disubstituted 1, 3, 4-oxadiazole and its analgesic, anti-inflammatory, anti-bacterial and anti-tubercular activity. Int. J. Chem. Tech. Res. 2010 Jul;2(3):1397-412.
9. Mali RK, Somani RR, Toraskar MP, Mali KK, Naik PP, Shirodkar PY, Synthesis of some antifungal and anti-tubercular 1, 2, 4-triazole analogues. Int. J. Chem. Tech. Res. 2009 Apr;1:168-73.
10. Arya V. A review on anti-tubercular plants. Int J Phar Tech Res. 2011;3:872-80.
11. Pawar PY, Bhise SB, Rindhe SS, Mane RA. Synthesis of substituted sulphoxaninolines as antimycobacterium tuberculosis agents. Int J Pharm Tech Res. 2009;1(2):252-5.
12. Pandey A, Rajavel R, Chandraker S, Dash D. Synthesis of Schiff bases of 2-amino-5-aryl-1, 3, 4-thiadiazole and its analgesic, anti-inflammatory and anti-bacterial activity. Journal of Chemistry. 2012 May 3;9(4):2524-31.
13. Visagaperumal D, Kumar RJ, Vijayaraj R, Anbalagan N. Microwave-induced synthesis of some new 3-substituted-1, 3-thiazolidin-4-ones for their potent antimicrobial and antitubercular activities. Int. J. Chem. Tech. Res. 2009;4:1048-51.
14. Somani RR, Balkund VD, Nikam SR, Shirodkar PY, Zope DB. Synthesis, antibacterial and anti-tubercular evaluation of some 1, 3, 4-oxadiazole based Mannich bases. International Journal of ChemTech Research. 2013 Jul;5(5):2588-92.
15. Prajapati K, Singh S, Pathak AK, Mehta P. QSAR analysis on some 8-methoxy quinoline derivatives as H37RV (MTB) inhibitors. Int J ChemTech Res. 2011;3(1):408-22.
16. Krátký M, Vinšová J, Novotná E, Mandíková J, Wsól V, Trejtnar F, Ulmann V, Stolaříková J, Fernandes S, Bhat S, Liu JO. Salicylanilide derivatives block Mycobacterium tuberculosis through inhibition of isocitrate lyase and methionine aminopeptidase. Tuberculosis. 2012 Sep 1;92(5):434-9.
17. Krátký M, Vinšová J, Novotná E, Mandíková J, Trejtnar F, Stolaříková J. Antibacterial activity of salicylanilide 4-(trifluoromethyl)-benzoates. Molecules. 2013;18(4):3674-88.
18. Ogawa H, Azuma M, Muto S, Nishioka Y, Honjo A, Tezuka T, Uehara H, Izumi K, Itai A, Sone S. IκB kinase β inhibitor IMD-0354 suppresses airway remodelling in a Dermatophagoides pteronyssinus-sensitized mouse model of chronic asthma. Clinical & Experimental Allergy. 2011 Jan 1;41(1):104-15.
19. Patil RB, Sawant SD. Synthesis, characterization, molecular docking and evaluation of antimicrobial activity of some 3-heteroaryl substituted chromen-2-one derivatives. Synthesis. Int.J. PharmTech Res. 2015;7(3):471-80.
20. Humaedi A, Arsiyanti A, Radji M. In Silico Molecular Docking Study of Gallic Acid and its Derivatives as Inhibitor BRAF Colon Cancer. International Journal of ChemTech Research, 2017,10(1): 310-315.

*****